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FIGURE 1 Adjusted Odds Ratio for Carotid Artery Stenosis by
PM2.5 Exposure
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Odds ratios adjusted for age, sex, race/ethnicity, body mass
index, dyslipidemia, hypertension, diabetes, physical activity
(yes/no), family history of cardiovascular disease, socioeconomic
status, and smoking. PM2.5 ¼ the mass concentration of
particles <2.5 mm in aerodynamic diameter; Q ¼ quartile.
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1151CAS relationship. Future studies should include
source- and component-speciﬁc analyses of PM2.5
exposure to determine which PM2.5 fractions are most
strongly associated with the observed increases in
cerebrovascular disease and CAS.*Jonathan D. Newman, MD, MPH
George D. Thurston, ScD
Kevin Cromar, PhD
Yu Guo, MA
Caron B. Rockman, MD
Edward A. Fisher, MD, PhD
*Jeffrey S. Berger, MD, MS
*Division of Cardiology
The Center for the Prevention of Cardiovascular Disease
New York University School of Medicine
227 East 30th Street, TRB Room 853
New York, New York 10016
E-mail: Jonathan.Newman@nyumc.org
or Jeffrey.Berger@nyumc.org
http://dx.doi.org/10.1016/j.jacc.2014.12.052
Please note: This research was supported by National Institutes of Health R01
Grant ES019584, as well as the New York University National Institute of
Environmental Health Sciences Center of Excellence (Grant ES00260). Dr.
Newman was partially funded by an Empire Clinical Research Investigator
Program by the New York State Department of Health to support Translational
Research in Inﬂammation and Atherosclerotic Disease (TRIAD). Dr. Berger was
partially funded by the National Heart, Lung, and Blood Institute of the National
Institutes of Health (RO1HL114978) and American Heart Association Clinical
Research Program (13CRP14410042). All other authors have reported that they
have no relationships relevant to the contents of this paper to disclose. The
authors are thankful for the participation and generosity of Life Line Screening,
who provided these data free of charge for the purposes of research and with no
restrictions on its use for research or resultant publications. This work has uti-
lized computing resources at the High Performance Computing Facility of the
Center for Health Informatics and Bioinformatics at New York University Lan-
gone Medical Center.REF ER ENCES
1. Gold DR, Mittleman MA. New insights into pollution and the cardiovascular
system: 2010 to 2012. Circulation 2013;127:1903–13.
2. Wellenius GA, Burger MR, Coull BA, et al. Ambient air pollution and the risk
of acute ischemic stroke. Arch Intern Med 2012;172:229–34.
3. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/
ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management
of patients with extracranial carotid and vertebral artery disease: executive
summary. J Am Coll Cardiol 2011;57:1002–44.
4. Savji N, Rockman CB, Skolnick AH, et al. Association between advanced age
and vascular disease in different arterial territories: a population database of
over 3.6 million subjects. J Am Coll Cardiol 2013;61:1736–43.
5. Grant EG, Benson CB, Moneta GL, et al. Carotid artery stenosis: gray-scale
and Doppler US diagnosis—Society of Radiologists in Ultrasound Consensus
Conference. Radiology 2003;229:340–6.Brain-Derived
Neurotrophic Factor as
a Marker for Immediate
Assessment of the
Success of Renal
Sympathetic DenervationThe renal sympathetic denervation (RSD) is an inter-
ventional treatment option in resistant hypertension
when optimal medical treatment fails, but this pro-
cedure has proved unsuccessful in some patients
(1). Therefore, identifying patients who would
potentially beneﬁt from RSD remains a major
clinical challenge. The sympathetic stimulation of
the cardiovascular system is partly regulated by
nerve growth factors and neurotrophic factors (2).
Brain-derived neurotrophic factor (BDNF) is the
most investigated member of the neurotrophin
family and is an important modulator of the
synaptic plasticity and activity of the sympathetic
nervous system (2). Therefore, the primary aim of
the present analysis was to evaluate whether
BDNF would indicate successful denervation of the
sympathetic nerve ﬁbers and provide immediate
assessment of a sufﬁcient RSD procedure.
A total of 100 consecutive patients with resistant
hypertension who underwent RSD were included in
the study. Ofﬁce and ambulatory blood pressure
measurements (ABPMs) were obtained at baseline
and 6 months after RSD. Ofﬁce blood pressure (BP)
was measured in each arm in the morning with pa-
tients in a sitting position after resting for at least
5 min. The arm with the higher BP was used for sub-
sequent readings. Venous blood samples for deter-
mination of BDNF levels were collected at baseline
TABLE 1 Brain-Derived Neurotrophic Factor Analysis and Association With
Blood Pressure Response After Renal Sympathetic Denervation
BDNF Analysis Baseline
2 h
After RSD
6-Month
Follow-Up
p Value
(2 h)
p Value
(6 Months)
BDNF levels
(all patients),
mg/l, n ¼ 100
48.6 (25.8-115.7) 29.4 (16.9-56.9) 42.8 (27.5-122.6) 0.001 0.48
Responder
(n ¼ 79)
Nonresponder
(n ¼ 21) p Value
BDNF baseline 50.7 (25.9-114.5) 42.8 (24.6-121.0) 0.13
BDNF 2 h after RSD 24.4 (14.7-54.3) 43.1(21.8-101.1) 0.04
BDNF at 6-month follow-up 42.8 (27.2-109.2) 47.7 (27.5-129.1) 0.5
Correlation Analysis
Correlation
Coefﬁcient p Value
Ofﬁce SBP/SBP reduction 0.54 0.001
Ambulatory SBP/ambulatory SBP reduction 0.36 0.002
BDNF fold change (2 h after RSD)/ofﬁce SBP reduction
(6-month follow-up)
0.51 0.001
BDNF fold change (2 h after RSD)/ambulatory SBP reduction
(6-month follow-up)
0.55 0.001
Blood pressure measurement, mm Hg Baseline 6-Month Follow-Up p Value
Ofﬁce blood pressure
Systolic 166.9  14.3 142.6  15.3 0.001
Diastolic 82.6  14.9 75.3  8.2 0.01
Ambulatory blood pressure
Systolic 155.7  12.2 144.3  11.8 0.001
Diastolic 81.8  12.8 76.7  11.1 0.015
Values are median (IQR) or mean  SD.
BDNF ¼ brain-derived neurotrophic factor; RSD ¼ renal sympathetic denervation; SBP ¼ systolic blood
pressure.
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1152and at 2 h and 6 months after RSD. A therapeutic
response was deﬁned as an ofﬁce systolic BP (SBP)
reduction of more than 10 mm Hg 6 months after
RSD. The pre-procedural and follow-up management
of these patients was recently published (3).
Six months after RSD, there was a signiﬁcant re-
duction in the mean ofﬁce SBP of 24.3 mm Hg
(p < 0.001). Further, we observed a signiﬁcant
reduction in BDNF serum levels at 2 h after RSD
(p < 0.001). Seventy-nine patients (79%) were clas-
siﬁed as responders, with a mean ofﬁce SBP reduc-
tion of more than 10 mm Hg 6 months after RSD.
There were signiﬁcant differences between BP re-
sponders and nonresponders regarding changes in
BDNF levels 2 h after RSD. Correlation analysis
revealed a signiﬁcant relationship between baseline
SBP values and RSD-related SBP reduction at the
6-month follow-up. In addition, there was a signif-
icant correlation between the decrease in BDNF
serum levels 2 h after RSD and SBP reduction at the
6-month follow-up (p < 0.001).
Data from the recently published randomized,
blinded HTN-3 (Renal Denervation in Patients WithUncontrolled Hypertension) trial failed to meet its
primary efﬁcacy endpoint because the study did not
show a signiﬁcant reduction in SBP in patients with
resistant hypertension 6 months after RSD com-
pared with a sham control arm. Accordingly, based
on the HTN-3 trial, there is leading evidence that
suggests that RSD may not be superior to a placebo
effect (4). These data contradict the results of
several previous nonrandomized trials (1). Conse-
quently, patient selection, operator experience,
and technical aspects of the procedure have been
considered as possible causes of these contrasting
results (1,4).
The present study proposes for the ﬁrst time an
immediate assessment of the success of sympathetic
nerve ﬁber denervation as reﬂected by BDNF as
a speciﬁc biomarker. BDNF is a key mediator of
neuronal and synaptic plasticity and regulates
neurotransmitter production in the sympathetic ner-
vous system; it is mainly associated with synaptic
regulation in humans (2). Decreased BDNF expression
contributes to an impaired density of sympathetic
activity and transmitter release (3). Importantly, in
the present study, we observed a signiﬁcant
decrease in BDNF levels immediately after RSD.
Moreover, there was a signiﬁcant correlation between
the extent of an early decrease in BDNF level and
SBP reduction at the 6-month follow-up (Table 1).
These results suggest an association between RSD-
related changes in BDNF levels and the degree of
success of the RSD procedure, an assumption that is in
line with the signiﬁcant differences that we observed
in the extent of early BDNF level changes between BP
responders (p < 0.001) and nonresponders (p ¼ 0.45)
(Table 1).
In accordance with previous investigations, we
observed a signiﬁcant SBP reduction in ofﬁce BP
readings as well as in ABPMs at the 6-month follow-
up (1,3,4). However, RSD-related changes in SBP
were more pronounced in ofﬁce BP measurements
than in ABPMs. These observations may be partly
explained by the statistical phenomenon of “regres-
sion to the mean,” which primarily affects ofﬁce BP
measurements and is also known from pharmaco-
logical trials.
In the present study, the immediate analysis
of BDNF levels was restricted to 2 h after RSD.
Additional, sequential BDNF analyses during the
early post-procedural period may lead to further im-
provements and accordingly needs to be evaluated to
appropriately implement the assessment of this
biomarker in clinical practice.
To the best of our knowledge, this is the ﬁrst study
that provides a biomarker-based approach for an
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cedure. The acute BDNF level reductionwas associated
with SBP reduction after 6 months of follow-up.
Moreover, the signiﬁcant difference in BDNF level
changes between BP responders and nonresponders
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Your Health”
The New Japanese Recommendation
for Physical Activity Based on
Dose-Response AnalysisWe read with interest the papers by Lee et al. (1) and
Wen et al. (2), both of which advocated for the health
beneﬁts of low doses of exercise, even performed atmoderate intensity. The American College of Sports
Medicine currently recommends completing the
equivalent of 30 min of moderate-to-vigorous
physical activity (MVPA) per day in bouts of at least
10 min. On the other hand, on the basis of the
results of their exercise dose–response analyses, Lee
et al. (1) and Wen et al. (2) both argue that an
exercise prescription of 5 min of running or 15 min
of walking per day can positively inﬂuence
cardiovascular mortality. The idea is to encourage
people to engage in physical activity (PA), even if
they cannot allocate the recommended daily 30 min.
On the basis of scientiﬁc evidence provided by
the (Japanese) National Institute of Health and Nutri-
tion, the Ministry of Health, Labour and Welfare
established and published the Japanese recommen-
dations for PA (or “ActiveGuide”) in March 2013 (3).
This document advises Japanese adults (i.e., 18 to
64 years of age) to perform 60 min of MVPA
per day without any consideration of the duration
of the bouts. In contrast to the reports of both Lee
et al. (1) and Wen et al. (2), these recommendations
include not only structured bouts of running or
walking, but also incorporate PA resulting from
housework, commuting, or shopping that are over
3 metabolic equivalents (METs). Most importantly,
the main message disseminated to the Japanese
population is “þ10,” representing “þ10 min of MVPA
per day.” To our knowledge, the implementation of
such PA recommendations in a governmental health
promotion policy is a world ﬁrst. It allows the
involvement of people who have already achieved
the targeted 60 min per day and encourages the most
sedentary individuals to become progressively more
active, thus targeting sedentary and more active
people with the same simple message.
The Japanese “þ10” recommendation mainly
results from the 2 following complementary reports.
The ﬁrst is a PA dose–response meta-analysis
completed in March 2011 (4). Data was extracted
from 26 cohort studies that investigated the relation
between the amounts of PA (summed from at least 2
PA domains) and mortality divided by the relative
risk for some noncommunicable diseases (including
cardiovascular diseases, cancer, dementia, and joint
or musculoskeletal diseases). We found that an
increment of 1 MET-h/week, which is equivalent to 2
to 3 min of MVPA per day, results in a 0.8%
reduction of the average relative risk (RR) (see
Table 14 in reference [4]). The second is Japan’s
National Health and Nutrition Survey, completed in
2010, in which the data collected from a sample of
7,876 people indicated that 61% of the Japanese
